Lenvatinib/Possible QT Prolonging Agents Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When given to healthy individuals, lenvatinib does not seem to affect heart rhythm. However, when lenvatinib combined in sick individuals with certain diseases, conditions (e.g. low levels of potassium or magnesium), and/or taking medicines that can affect heart rhythm, lenvatinib may increase the risk for heart rhythm changes.
What might happen:
Taking lenvatinib with other agents that can affect your heart rhythm may increase your risk of irregular heartbeat, which may be life-threatening.
What you should do about this interaction:
Make sure that your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Let your doctor know if you have any heart conditions. Your doctor may want to perform an electrocardiogram (ECG) and check the electrolytes in your blood periodically while you are taking lenvatinib to make sure you are not at risk for an irregular heartbeat. Let your doctor know right away if you have any dizziness or fainting episodes, or notice an irregular heartbeat/palpitations.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Lenvima (lenvatinib) US prescribing information. Eisai Inc. December, 2021.
- 2.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
- 3.Abu Rmilah AA, Lin G, Begna KH, Friedman PA, Herrmann J. Risk of QTc Prolongation Among Cancer Patients Treated with Tyrosine Kinase Inhibitors. Int J Cancer. 2020 May 25.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.